ENDO: Continuing Semaglutide Aids Weight Loss in Overweight, Obese

THURSDAY, March 25, 2021 -- For overweight and obese individuals who completed a 20-week run-in with subcutaneous semaglutide, continuing treatment is associated with a greater mean body weight change compared with switching to placebo, according to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news